Oncometabolites in urine - a new opportunity for detection and prognosis of the clinical progress of verified prostate cancer-a pilot study.
Prostate cancer
biomarkers
liquid chromatography with tandem mass spectrometry
oncometabolites
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
07
08
2021
accepted:
23
01
2021
entrez:
3
11
2022
pubmed:
4
11
2022
medline:
8
11
2022
Statut:
ppublish
Résumé
Oncometabolites provide a new approach towards the diagnostics and prognosis of the clinical progress of prostate cancer (PCa). This study is about the diagnostic and predictive value of a panel of urinary oncometabolites (ethanolamine, kynurenine, β-alanine, α-alanine, leucine, isoleucine, γ-aminobutyric acid, and sarcosine) and correlation with prostate-specific antigen (PSA) and Gleason score in patients diagnosed with prostate cancer. The participants in this cross-sectional study were divided into PCa group (101 patients who matched the including criteria, average age 71) and control group (52 individuals, with no evidence of malignancy, without oncological and other chronic diseases, and without prostate gland pathology, average age 40). The criteria to be included in the PCa group were as follows: i) being diagnosed with prostate cancer, based on digital rectal examination (DRE), prostate ultrasound investigation, or biopsy; ii) not being subjected to a surgical or any other treatment; iii) not having any other concomitant oncological diseases, renal failure, diabetes mellitus. The urinary concentration of the selected metabolites was established through high-performance liquid chromatography with tandem mass spectrometry detection (HPLC-MS/MS). The comparison of both groups established a significantly different elevated concentration of ethanolamine, sarcosine and kynurenine, and a significantly different decreased concentration of β-alanine and isoleucine in PCa group. No changes of the values were detected in the PCa group with PSA levels below and above 10 ng/mL and Gleason score below and above 6 (p > 0.05). To test whether combination of several variables is more powerful in discriminating between PCa and control group multiple logistic regression analysis was performed. A model including ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine demonstrated negative predictive power (NPP) 76.2% and positive predictive power (PPP) 81.8%. Urinary concentrations of ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine in PCa group differ significantly from that of control group. New expanded population studies are needed to discuss our results.
Sections du résumé
BACKGROUND
BACKGROUND
Oncometabolites provide a new approach towards the diagnostics and prognosis of the clinical progress of prostate cancer (PCa). This study is about the diagnostic and predictive value of a panel of urinary oncometabolites (ethanolamine, kynurenine, β-alanine, α-alanine, leucine, isoleucine, γ-aminobutyric acid, and sarcosine) and correlation with prostate-specific antigen (PSA) and Gleason score in patients diagnosed with prostate cancer.
METHODS
METHODS
The participants in this cross-sectional study were divided into PCa group (101 patients who matched the including criteria, average age 71) and control group (52 individuals, with no evidence of malignancy, without oncological and other chronic diseases, and without prostate gland pathology, average age 40). The criteria to be included in the PCa group were as follows: i) being diagnosed with prostate cancer, based on digital rectal examination (DRE), prostate ultrasound investigation, or biopsy; ii) not being subjected to a surgical or any other treatment; iii) not having any other concomitant oncological diseases, renal failure, diabetes mellitus. The urinary concentration of the selected metabolites was established through high-performance liquid chromatography with tandem mass spectrometry detection (HPLC-MS/MS).
RESULTS
RESULTS
The comparison of both groups established a significantly different elevated concentration of ethanolamine, sarcosine and kynurenine, and a significantly different decreased concentration of β-alanine and isoleucine in PCa group. No changes of the values were detected in the PCa group with PSA levels below and above 10 ng/mL and Gleason score below and above 6 (p > 0.05). To test whether combination of several variables is more powerful in discriminating between PCa and control group multiple logistic regression analysis was performed. A model including ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine demonstrated negative predictive power (NPP) 76.2% and positive predictive power (PPP) 81.8%.
DISCUSSION
CONCLUSIONS
Urinary concentrations of ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine in PCa group differ significantly from that of control group. New expanded population studies are needed to discuss our results.
Identifiants
pubmed: 36326306
doi: 10.55730/1300-0144.5363
pmc: PMC10390161
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Sarcosine
Z711V88R5F
Kynurenine
343-65-7
Isoleucine
04Y7590D77
Ethanolamines
0
beta-Alanine
11P2JDE17B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-706Références
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Anal Chem. 2010 Nov 1;82(21):9022-7
pubmed: 20939533
Int J Med Sci. 2017 Jan 1;14(1):1-12
pubmed: 28138303
Metabolites. 2017 Feb 23;7(1):
pubmed: 28241496
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Metabolomics. 2017;13(5):52
pubmed: 28804274
Clin Chem. 2013 Jan;59(1):138-46
pubmed: 23150057
J Urol. 2011 Mar;185(3):869-75
pubmed: 21239008
Magn Reson Med. 2008 Jul;60(1):33-40
pubmed: 18581409
Int J Mol Sci. 2013 Jun 17;14(6):12620-49
pubmed: 23774836
Nature. 2009 Feb 12;457(7231):910-4
pubmed: 19212411
Curr Protoc Hum Genet. 2017 Apr 6;93:A.3O.1-A.3O.7
pubmed: 28384398
Metabolites. 2021 Mar 19;11(3):
pubmed: 33808897
Anal Chem. 2011 Jul 15;83(14):5735-40
pubmed: 21635006
Eur Urol. 2010 Jul;58(1):12-8; discussion 20-1
pubmed: 20117878
J Clin Oncol. 2011 Jun 1;29(16):2185-90
pubmed: 21464416
Sci Rep. 2016 Dec 02;6:38243
pubmed: 27910903
Prostate Cancer Prostatic Dis. 2011 Jun;14(2):166-72
pubmed: 21321584
Urol Oncol. 2011 Sep-Oct;29(5):572-81
pubmed: 21930089